The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.
Mattias Wieloch
Advertisement
Articles by Mattias Wieloch
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
3
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5